Shrinking the Surgical Robot: J&J’s New Battle

Johnson & Johnson's table-integrated Ottava robot clears its first human trial, opening an FDA pathway to bring robotic surgery to smaller rooms

22 May 2026

Johnson & Johnson has released successful data from the first human clinical trial of its Ottava robotic surgical system. The results mark a critical regulatory step for the healthcare conglomerate as it prepares to challenge the long-standing dominance of Intuitive Surgical in the soft-tissue robotics market.

The study, which evaluated 30 patients undergoing gastric bypass surgery across six US hospitals, met all primary safety and performance targets within 30 days. Clinicians completed every operation robotically without needing to switch to conventional surgical methods.

By integrating four robotic arms directly into a standard operating table, the design eliminates the external carts and overhead structures required by older platforms. This compact footprint allowed the technology to be deployed in operating rooms as small as 243 square feet. Crucially, five of the six testing sites had never hosted robotic surgery before due to space constraints.

"These results demonstrate that the novel architecture can integrate into existing infrastructure and remove practical barriers to broader adoption," said Peter Schulam, chief scientific officer for Johnson & Johnson MedTech.

The company has submitted the clinical data to the US Food and Drug Administration to support an application for De Novo classification. This regulatory pathway is reserved for novel medical devices that lack a direct market predecessor. J&J is seeking commercial clearance for a range of general surgeries in the upper abdomen, including gastric sleeve and hernia repairs.

Historically, the soft-tissue surgical robotics sector has remained highly concentrated. Intuitive Surgical has controlled the market for more than two decades, though Medtronic entered the US space late last year with its own platform. Market analysts suggest that regulatory clearance for Ottava would establish a three-company field, altering procurement strategies and infrastructure investments for hospital groups.

While robotic-assisted surgery can lower patient recovery times, millions of patients currently undergo abdominal procedures in facilities that lack the physical space for traditional, bulkier systems. If approved by regulators, the smaller design of the platform could expand advanced surgical capabilities to smaller community hospitals and ambulatory surgical centers.